Nucleic acid drugs are a new type of biological drugs that use nucleic acids as the active ingredients. They can regulate the expression or function of target genes at the molecular level, and achieve therapeutic effects by correcting or compensating for the abnormality of genes or their products. Nucleic acid drugs have attracted much attention in recent years because of their great potential in treating various diseases, especially rare diseases caused by genetic defects. In this article, I will explain why nucleic acid drugs are worth developing from four aspects: market and drug demand, distinctive and irreplaceable role, successful cases, and technical difficulty.
First of all, there is a huge market and drug demand for nucleic acid drugs. According to the World Health Organization (WHO), there are more than 7,000 rare diseases in the world, affecting about 400 million people. About 80% of rare diseases are caused by single gene abnormalities, and about 95% of them have no effective treatment. These patients have a high unmet medical need and a strong willingness to pay for new therapies. Nucleic acid drugs have obvious advantages in treating rare diseases because of their unique physical, chemical and pharmacological characteristics. They can target specific genes or gene products with high specificity and affinity, and modulate their expression or function in a reversible and controllable manner. They can also overcome some of the limitations of traditional small molecule drugs or protein drugs, such as poor bioavailability, low stability, immunogenicity, toxicity and side effects.
Secondly, nucleic acid drugs have a distinctive and irreplaceable role in gene therapy. Gene therapy is a promising strategy to treat diseases by introducing, inhibiting or correcting genes. At present, nucleic acid drug therapy is divided into three main directions: introducing normal genes to supplement the function lost by gene mutation, inhibiting or silencing abnormal genes through RNA interference (RNAi), and directly correcting abnormal gene structure through gene editing (CRISPR-Cas9). These are all unique treatments of nucleic acid drugs that cannot be achieved by other types of drugs. For example, RNAi can selectively knock down the expression of disease-causing genes or proteins without affecting the normal function of other genes or proteins. Gene editing can precisely modify the DNA sequence of target genes and permanently correct the genetic defects.
Thirdly, there are successful cases of nucleic acid drugs that have been approved for marketing or are in clinical trials. For example, Onpattro (patisiran) is the first RNAi drug approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR), a rare and fatal disease that causes nerve damage and heart failure. Onpattro can reduce the production of transthyretin (TTR) protein in the liver and prevent its accumulation in tissues and organs. Another example is Luxturna (voretigene neparvovec), which is the first gene therapy drug approved by the FDA in 2017 for the treatment of inherited retinal dystrophy (IRD), a rare eye disease that causes blindness. Luxturna can deliver a normal copy of the RPE65 gene to the retinal cells and restore their ability to produce a functional enzyme that is essential for vision. Moreover, there are more than 300 nucleic acid drugs in various stages of clinical development for different indications, such as cancer, viral infections, cardiovascular diseases, metabolic diseases and neurological diseases.
Finally, there is a certain technical difficulty in developing nucleic acid drugs, which is helpful to promote the development of innovative technologies, to improve the quality and efficacy of drugs, and to ensure the longevity of drugs. Nucleic acid drugs face many challenges in terms of design, synthesis, delivery, safety and regulation. For example, nucleic acids are easily degraded by enzymes in vivo and have poor membrane permeability. Therefore, they need to be modified or encapsulated by various carriers to enhance their stability and delivery efficiency. However, these modifications or carriers may also affect the activity or specificity of nucleic acids or cause immunogenicity or toxicity. Therefore, it requires constant innovation and optimization to overcome these obstacles and achieve optimal therapeutic outcomes.
In conclusion, nucleic acid drugs are worth developing because they have a huge market potential, a distinctive therapeutic mechanism, a proven track record and a challenging technical barrier. They represent a new frontier of biotechnology and medicine that can bring hope and benefit to millions of patients suffering from various diseases.
